3rd Quarter - Report
THE D MAJOR GROUP for ALLERGAN INC (FORMERLY ACTAVIS INC )
Firm
Income
$48,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocate for voluntary best practices related to pharmaceutical pricing. Monitor H.R. 2430, the FDA Reauthorization Act of 2017; S. 934, the Food and Drug Reauthorization Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Analyst for the Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for the House Republican Conference |
Budget/Appropriations BUD
Monitor FDA funding for inspection of counterfeit medicines and separately, oversight of compounding medicines -- both as related to the FY 2018 Agriculture Appropriations bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Policy Analyst for Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for House Republican Conference |
Copyright/Patent/Trademark CPT
Advocate for Inter Partes Review (IPR) reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Policy Analyst for Senate Republican Policy Comt. |
| BRENDA REESE | Conference Coordinator for House Republican Conference |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.